Convergence Investment Partners’s GSK GSK Stock Holding History

Convergence Investment Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-385	Closed	-$19K	–	554
2018 Q1	$19K	Buy	+385	New	+$17.9K	﹤0.01%	604
2015 Q2	–	Sell	-4,046	Closed	-$233K	–	376
2015 Q1	$233K	Buy	4,046 +67	+2%	+$3.84K	0.03%	338
2014 Q4	$213K	Sell	3,979 -15	-0.4%	-$839	0.03%	331
2014 Q3	$230K	Buy	3,994 +160	+4%	+$9.81K	0.03%	331
2014 Q2	$256K	Sell	3,834 -1,784	-32%	-$121K	0.03%	328
2014 Q1	$375K	Sell	5,618 -1,960	-26%	-$133K	0.06%	290
2013 Q4	$506K	Sell	7,578 -1,452	-16%	-$94.1K	0.08%	261
2013 Q3	$566K	Sell	9,030 -2,532	-22%	-$163K	0.12%	196
2013 Q2	$722K	Buy	+11,562	New	+$734K	0.19%	162

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Convergence Investment Partners's GSK Position: Q2 2018 in Review

Convergence Investment Partners sold out of GSK (GSK) in Q2 2018, closing a stake of 385 shares — an estimated $19K sold.

Convergence Investment Partners first reported a position in GSK in Q2 2013 and held it in 9 quarters. The position peaked at $722K in Q2 2013. 787 funds tracked by Wall St. Rank hold GSK as of Q2 2018.

Convergence Investment Partners reported no remaining GSK position as of Q2 2018 after selling out during the quarter.
Convergence Investment Partners sold 385 GSK shares in Q2 2018, an estimated $19K.
Convergence Investment Partners first reported a position in GSK in Q2 2013 and held it in 9 quarters.
Convergence Investment Partners's GSK position peaked at $722K in Q2 2013.
787 funds tracked by Wall St. Rank held GSK as of Q2 2018.

Based on Convergence Investment Partners's 13F filing for Q2 2018, filed 7 Aug 2018.